ADVERTISEMENT

biotech

Treating Toxoplasmosis
Jef Akst | Sep 25, 2015 | 2 min read
While one company hikes the price of an old drug to treat the parasitic infection, academic researchers report that an approved blood pressure medication could be just what the doctor ordered.
The Sounds of Silence
Jenny Rood | Sep 1, 2015 | 8 min read
Science-based tinnitus therapeutics are finally coming into their own.
Hearing Help
Kate Yandell | Sep 1, 2015 | 10+ min read
For decades, the only remedies for hearing loss were devices such as hearing aids or cochlear implants. Now, the first pharmaceutical treatments may be on the way.
 
TS Live: Pharma Feast
Kerry Grens | Aug 26, 2015 | 1 min read
A sampling of the biggest acquisitions reshaping the life sciences industry in 2015
FDA Approves 3-D–Printed Drug
Jef Akst | Aug 4, 2015 | 1 min read
The US Food and Drug Administration green lights the first medicine produced by a 3-D printer for use in the human body.
Tasty Visuals
Kerry Grens | Jun 23, 2015 | 2 min read
A newly approved visual aid translates the appearance of objects to electrical stimulation on the tongue.
Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
Custom Creatures?
Kerry Grens | Jan 6, 2015 | 1 min read
San Francisco-based biotech wants to see its technology applied for inventing new organisms.
Incentivizing Breakthroughs
Grant Campany | Dec 1, 2014 | 4 min read
With scientific funding on shaky ground, big-dollar competitions offer a new way for life-science innovators to bring their ideas to fruition.
Roche Buys Biotech for $8.3B
Jef Akst | Aug 27, 2014 | 1 min read
The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.
Biotech Terminates IPO
Jyoti Madhusoodanan | Aug 14, 2014 | 2 min read
The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 
Merck Snaps Up Biotech for $3.85B
Tracy Vence | Jun 10, 2014 | 1 min read
The drug giant will acquire Cambridge, Massachusetts-based Idenix Pharmaceuticals, which is focused on developing treatments for hepatitis C.
The Promise of Nanomedicine
Jef Akst | Apr 8, 2014 | 2 min read
At AACR, scientists discuss the growing interest in nanotechnology and how it can be used to study, diagnose, and treat cancer.
Incubator Boom
Kerry Grens | Mar 1, 2014 | 7 min read
From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?
 
New Year’s Biotech IPO Boom?
Tracy Vence | Feb 3, 2014 | 1 min read
January was a profitable month for biotech companies going public, Burrill & Company says.
Penetrating the Brain
Megan Scudellari | Nov 1, 2013 | 8 min read
Researchers use molecular keys, chisels, and crowbars to open the last great biochemical barricade in the body—the blood-brain barrier.
Geron’s Stem Cell Program Sold
Jef Akst | Oct 2, 2013 | 2 min read
The company, which launched the first ever clinical trial for a human embryonic stem cell therapy before shuttering its stem cell arm, has finally struck a deal with BioTime.
Remaking a Classic
Megan Scudellari | Sep 1, 2013 | 9 min read
Companies are bursting at the seams with tools to engineer pharma’s next magic bullet: the new and improved antibody.
Week in Review: August 26–30
Tracy Vence | Aug 30, 2013 | 3 min read
New model for neurodevelopment; more biotechs going public; how a virus jumped from mammals to birds; statin side effect linked to genetic variant
Opinion: AIA Does Not Discriminate
G. Nagesh Rao | Aug 21, 2013 | 3 min read
The America Invents Act (AIA) was a step in the right direction for US competitiveness and open innovation.
ADVERTISEMENT